Our newest portfolio stocks pulled back from their recent 52-week high, so we're buying more
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
Jim Cramer
Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
2 health stocks are buys. They're pretty disappointed with Trump RFK Jr.'s pick for HHS
We are purchasing 25 shares of Danaher at approximately $229 each. Following Monday's trade, Jim Cramer's Charitable Trust will own…
Jim Cramer's Top 10 Things to Watch for in the Stock Market on Friday
My Top 10 Things to Watch for Friday, Nov. 15 1. President-elect Donald Trump's decision to nominate prominent vaccine skeptic…
Jim Cramer on Eli Lilly (LLY) after Trump picks RFK Jr. to lead HHS
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…
We are increasing our price target on GEHC, looking beyond a mixed quarter to next year's catalysts.
GE Healthcare reported a mixed quarter before Wednesday's opening bell. While revenue declined slightly, an improvement in earnings along with…
Abbott 'very cheap' after surprising legal victory validates our conviction
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…
Palo Alto Stocks Boosted by Contract News, Abbott Labs Braces for Ruling
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Danaher puts bioprocessing back into growth. We are raising our rating to buy
Danaher shares fell on Tuesday even though the life sciences company regained growth in its key bioprocessing business in the…
Abbott Labs shines with strong quarter and buyback announcement
Medical device maker Abbott Laboratories on Wednesday delivered better-than-expected quarterly results and raised its profit forecasts for the third consecutive…